StemCells, Inc. today announced that it has received a manufacturing license for its cell processing facility from the State of California Department of Health Services, Food and Drug branch. This enables the Company to manufacture its neural cell therapy product, HuCNS-SC for clinical trials.

Stem Cells Inc. filed an Investigational New Drug application ( IND) with the U.S. FDA to begin a clinical trial of human neural stem cells for the treatment of Batten disease, a rare and fatal neurodegenerative genetic condition affecting infants and children. The trial is on clinical hold. Additionally, StemCells intends to apply for funding from the Proposition 71 funds.

See StemCells's press release here.